Sage Therapeutics Inc (FRA:SG7)
€ 10.175 -0.385 (-3.65%) Market Cap: 589.40 Mil Enterprise Value: -65.07 Mil PE Ratio: 0 PB Ratio: 0.95 GF Score: 49/100

SAGE Therapeutics Inc at Stifel Healthcare Conference Transcript

Nov 19, 2019 / 03:20PM GMT
Release Date Price: €130 (-0.76%)
Paul Andrew Matteis
Stifel, Nicolaus & Company, Incorporated, Research Division - Co-Head of the Biotech Team, MD & Senior Analyst

Great. Thanks. My name is Paul Matteis. I'm a biotech analyst at Stifel. Happy to be hosting the Sage team with me, Kimi Iguchi, CFO; Steve Kanes, Chief Medical Officer. I think we'll just kick it off. I'm sure everyone knows Sage quite well. But maybe, Steve, do you want to just briefly talk about the 217 clinical studies, timing of MOUNTAIN enrollment, when it was completed and what the next catalysts are? Or do you want to do it, Kimi?

Kimi E. Iguchi
Sage Therapeutics, Inc. - CFO & Treasurer

No, but let me jump in. Maybe I can just give a couple of highlights from our earnings call.

Paul Andrew Matteis
Stifel, Nicolaus & Company, Incorporated, Research Division - Co-Head of the Biotech Team, MD & Senior Analyst

Please. Yes. Go ahead.

Kimi E. Iguchi
Sage Therapeutics, Inc. - CFO & Treasurer

I think because I know

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot